Because of the aforementioned evidence, we hypothesized that recombinant IL-19 treatment increases hematoma resolution, expression of scavenger receptors on microglia/macrophages, M2 microglia, reduces ventricular dilatation, and improves short- and long-term neurological deficits and that the beneficial effects may be mediated by the activation of the IL-20R1/ERK/Nrf2/CD163 signaling pathway. This evidence concerns the gene IL20RA and hematoma.